ArticleInternational immunopharmacology2013
Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.
Article in International immunopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.Molecules (Basel, Switzerland) · 2020Pooled it
- MiR‑365b‑5p and MiR‑3614‑5p are elevated in PBMCs of systemic lupus erythematosus and exhibit potential as complementary diagnostic indicators.Clinical rheumatology · 2026Article
- Mechanism study of miR-324-3p driving myocardial infarction progression through regulation of myocardial inflammation.Journal of cardiothoracic surgery · 2026Article
- Aberrant STAT3 activation and overproduction of IL-21 in systemic lupus erythematosus: role of miR-155 and miR-21 in target genesFrontiers in immunology · 2026Article
- The anti-inflammatory effect of myrrh ethanolic extract in comparison with prednisolone on an autoimmune disease rat model induced by silicate.Inflammopharmacology · 2022Article
- Epigenetic Alterations in Immune Cells of Systemic Lupus Erythematosus and Therapeutic Implications.Cells · 2022Review
- MicroRNAs in Lupus Nephritis-Role in Disease Pathogenesis and Clinical Applications.International journal of molecular sciences · 2021Review
- Hydroxychloroquine effects on miR-155-3p and miR-219 expression changes in animal model of multiple sclerosis.Metabolic brain disease · 2020Article
- Urinary biomarkers in lupus nephritis.Journal of translational autoimmunity · 2020Review
- Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis.Animal models and experimental medicine · 2019Review
- New therapeutic strategies in systemic lupus erythematosus management.Nature reviews. Rheumatology · 2019Review
- Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.Mediators of inflammation · 2018Review
- Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren's syndrome.Annals of the rheumatic diseases · 2018Article
- Transcriptomic profiling in human mesangial cells using patient-derived lupus autoantibodies identified miR-10a as a potential regulator of IL8.Scientific reports · 2017Article
- Pathogenic mechanism of miR-21 in autoimmune lymphoid hyperplasia syndrome.Oncology letters · 2017Article
- DNA methylation in systemic lupus erythematosus.Epigenomics · 2017Review
- 'Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients'.Scientific reports · 2016Article
- MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus.Clinical immunology (Orlando, Fla.) · 2016Article
- Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Inflammopharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Determining alterations to disease-associated miRNAs induced by specific therapeutics may allow the use of tailored therapy in lupus. We determined miRNA alterations in female NZB/W lupus mice treated with hydroxychloroquine (HCQ) or prednisone (PRED) for 12 weeks beginning at 24 weeks-of-age. B cell, PBMC, and urinary miR-let-7a expression were decreased with HCQ or PRED treatment. HCQ or PRED treatment reduced miR-21 expression in mesangial cells, T cells, pDCs, PBMCs, and the urine. MiR-146a expression was reduced in mesangial cells with HCQ treatment and in pDCs with HCQ or PRED treatment. PRED treatment increased miR-155 expression in mesangial, B, and T cells and PBMCs yet decreased miR-155 expression in pDCs and the urine. In vitro studies confirmed that HCQ or PRED's anti-inflammatory actions are dependent on their ability to inhibit miRNA expression. Our studies indicate that lupus therapeutics may work, in part, by altering the expression of disease-associated miRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.